Application of yod1 gene in preparation of drugs for inducing differentiation therapy of leukemia
A technology for inducing differentiation and treating drugs, which is applied in the field of medicine and biology, can solve the problems of YOD1 gene and leukemia cell differentiation that have not been reported in the literature, and achieve the effect of enhancing NBT reducing ability and reducing the ratio of nucleus to cytoplasm
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0026] Seven YOD1 siRNAs targeting different sequences (SEQ ID NO:3-SEQ ID NO:9) and the negative control NC were introduced into NB4 cells by lipofection (Dr. Lingtao Wu, University of Southern California, USA). After 72 hours, the cells were harvested, and the cells were lysed with the cell lysate to extract proteins, and then Western blot was performed with YOD1 antibody (purchased from Proteintech). As a result, it was found that all the above YOD1 siRNAs (SEQ ID NO:3-SEQ ID NO:9) could effectively inhibit the protein expression of YOD1. See results figure 1 .
Embodiment 2
[0028] Two YOD1 siRNAs targeting different sequences with different silencing efficiencies (SEQ ID NO:3,SEQ ID NO:4) and the negative control NC were introduced into leukemia NB4, U937 and HL60 cells by lipofection (purchased from the Cell Bank of the Chinese Academy of Sciences). After treatment D1, D3 and D5, counts were performed using a hemocytometer. The results showed that YOD1 siRNA (SEQ ID NO:3, SEQ ID NO:4) could significantly inhibit the proliferation of leukemia NB4, U937 and HL60 cells. See results figure 2 .
Embodiment 3
[0030] YOD1 siRNA (SEQ ID NO:3, SEQ ID NO:4) targeting different sequences with different silencing efficiencies and the negative control NC were introduced into NB4 cells by lipofection. The cells were collected after treatment on D3 and D5, and the expression of the differentiation-specific antigen CD11b on the cell surface was detected. Cells were rinsed with ice PBS for 3 times and then incubated with 1% BSA and CD11b-PE-labeled monoclonal antibody in the dark for 60 min. After washing with PBS, the cells were detected by flow cytometry and analyzed by CellQuest Pro software. As a result, it was found that YOD1 siRNA (SEQ ID NO:3, SEQ ID NO:4) can significantly promote the expression of the specific antigen CD11b on the surface of leukemia cells. See results image 3 .
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com